Results 171 to 180 of about 7,525,117 (401)

The Mismatch Between Life Insurance Holdings and Financial Vulnerabilities: Evidence from the Survey of Consumer Finances [PDF]

open access: yes
Using the 1995 Survey of Consumer Finances and an elaborate life-cycle model, we quantify the potential financial impact of each individual's death on his or her survivors, and we measure the degree to which life insurance moderates these consequences ...
B. Douglas Bernheim   +3 more
core  

Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT) is the second‐most common inherited bleeding disorder worldwide, afflicting one in 4000–5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the ...
Hanny Al‐Samkari   +5 more
wiley   +1 more source

MENENTUKAN PREMI TAHUNAN UNTUK TIGA ORANG PADA ASURANSI JIWA HIDUP GABUNGAN (JOINT LIFE)

open access: yesE-Jurnal Matematika, 2015
Life insurance products consist of a single life insurance and joint life insurance. Joint life is a state where the rule die life is a combination of two or more factors, such as the husband-wife, parent-child.
TRI YANA BHUANA   +2 more
doaj  

Study protocol: the Australian genetics and life insurance moratorium-monitoring the effectiveness and response (A-GLIMMER) project. [PDF]

open access: yesBMC Med Ethics, 2021
Tiller J   +10 more
europepmc   +1 more source

Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACTHereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari   +22 more
wiley   +1 more source

Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study. [PDF]

open access: yesJ Cancer Res Clin Oncol, 2022
Thong MSY   +13 more
europepmc   +1 more source

Financial Advisers' and Key Informants' Perspectives on the Australian Industry-Led Moratorium on Genetic Tests in Life Insurance.

open access: yesPublic Health Genomics, 2023
Haining CM   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy